Laura A. Dawson, MD, on Sorafenib vs Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma

Posted: Tuesday, January 31, 2023

Laura A. Dawson, MD, of Canada’s Princess Margaret Cancer Centre, discusses the clinical implications of her phase III findings, which may define a new standard treatment option for patients with advanced hepatocellular carcinoma, especially in the presence of macrovascular invasion. The NRG/RTOG1112 study showed that stereotactic body radiation therapy administered prior to sorafenib vs sorafenib alone, improved overall survival, progression-free survival, and time to disease progression.